In SKOV3 ovarian cancer cells, Padbury et al. demonstrated that the pharmacological activation of TRPC3 significantly increased extracellular vesicle (EV) release, while its inhibition suppressed EV output [43]. Here, TRPC3 is linked to ovarian carcinoma.